Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05939947 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis
A Phase 1 study, sponsored by Alentis Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT05939947 is a Phase 1 study that has completed, run by Alentis Therapeutics. The registered enrollment target is 41 participants.
The verdict
NCT05939947, a Phase 1 study, has completed, sponsored by Alentis Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.
Interventions
- DRUG Placebo
- DRUG ALE.F02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05939947
The ClinicalTrials.gov registry entry for NCT05939947 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alentis Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05939947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05939947 about?
NCT05939947 is a clinical study titled "A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis". The purpose of this study is to evaluate how a human body processes ALE.F02 (pharmacokinetics profile) in patients with impaired liver function.
What is the current status of trial NCT05939947?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-04-01. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT05939947?
The interventions under investigation include: Placebo (DRUG), ALE.F02 (DRUG).
Who is sponsoring clinical trial NCT05939947?
This trial is sponsored by Alentis Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.